Tryptophanyl-tRNA synthetase (WARS) expression in uveal melanoma – possible contributor during uveal melanoma progression

References

• Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on Incidence, Treatment, and Survival (SEER 1973–2013). Ocul Oncol Pathol. 2018;4:145–151.
   PubMed Web of Science ®Google Scholar
• Posch C, Latorre A, Crosby MB, et al. Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles. Biomed Microdevices. 2015;17:15.
   PubMed Web of Science ®Google Scholar
• Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36:109–140.
   PubMed Web of Science ®Google Scholar
• Nezu N, Goto H, Umazume K, et al. Clinical analysis of uveal melanoma. Nippon Ganka Gakkai Zasshi. 2017;121:413–418.
   PubMedGoogle Scholar
• Moschos MM, Dettoraki M, Androudi S, et al. The role of histone deacetylase inhibitors in uveal melanoma: current evidence. Anticancer Res. 2018;38:3817–3824.
   PubMed Web of Science ®Google Scholar
• Stalhammar G, See TRO, Phillips S, et al. Digital image analysis of BAP-1 accurately predicts uveal melanoma metastasis. Transl Vis Sci Technol. 2019;8:11.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Schwartz GK, Tezel T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101:38–44.
   PubMed Web of Science ®Google Scholar
• Lee HC, Lee ES, Uddin MB, et al. Released tryptophanyl-tRNA synthetase stimulates innate immune responses against viral infection. J Virol. 2019;93.
   Web of Science ®Google Scholar
• Paley EL, Paley DE, Merkulova-Rainon T, et al. Hypoxia signature of splice forms of tryptophanyl-tRNA synthetase marks pancreatic cancer cells with distinct metastatic abilities. Pancreas. 2011;40:1043–1056.
   PubMed Web of Science ®Google Scholar
• Lu S, Wang LJ, Lombardo K, et al. Expression of indoleamine 2, 3-dioxygenase 1 (IDO1) and tryptophanyl-tRNA synthetase (WARS) in gastric cancer molecular subtypes. Appl Immunohistochem Mol Morphol. 2019;1.
   PubMedGoogle Scholar
• Morita A, Miyagi E, Yasumitsu H, et al. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics. 2006;6:5880–5890.
   PubMed Web of Science ®Google Scholar
• Arnouk H, Merkley MA, Podolsky RH, et al. Characterization of molecular markers indicative of cervical cancer progression. Proteomics Clin Appl. 2009;3:516–527.
   PubMed Web of Science ®Google Scholar
• Ghanipour A, Jirstrom K, Ponten F, et al. The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:2949–2956.
   PubMed Web of Science ®Google Scholar
• Lee CW, Chang KP, Chen YY, et al. Overexpressed tryptophanyl-tRNA synthetase, an angiostatic protein, enhances oral cancer cell invasiveness. Oncotarget. 2015;6:21979–21992.
   PubMedGoogle Scholar
• Seshaiah P, Andrew DJ, Kimble J. WRS-85D: A tryptophanyl-tRNA synthetase expressed to high levels in the developing Drosophila salivary gland. Mol Biol Cell. 1999;10:1595–1608.
   PubMed Web of Science ®Google Scholar
• Yang D, Nakada-Tsukui K, Ohtani M, et al. Identification and cloning of genes associated with the guinea pig skin delayed-type hypersensitivity reaction. J Biochem. 2001;129:561–568.
   PubMed Web of Science ®Google Scholar
• Wakasugi K, Slike BM, Hood J, et al. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci U S A. 2002;99:173–177.
   PubMed Web of Science ®Google Scholar
• Stana A, Vodnar DC, Marc G, et al. Antioxidant activity and antibacterial evaluation of new thiazolin-4-one derivatives as potential tryptophanyl-tRNA synthetase inhibitors. J Enzyme Inhib Med Chem. 2019;34:898–908.
   PubMed Web of Science ®Google Scholar
• Jin M. Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications. Exp Mol Med. 2019;51:1.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun D, Sun W, et al. Ras-PI3K-AKT signaling promotes the occurrence and development of uveal melanoma by downregulating H3K56ac expression. J Cell Physiol. 2019.
   Web of Science ®Google Scholar
• Ye M, Hu D, Tu L, et al. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci. 2008;49:497–504.
   PubMed Web of Science ®Google Scholar
• Babchia N, Calipel A, Mouriaux F, et al. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Invest Ophthalmol Vis Sci. 2010;51:421–429.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay C, Kim DW, Gombos DS, et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer. 2016;122:2299–2312.
   PubMed Web of Science ®Google Scholar
• Yang XL, Schimmel P, Ewalt KL. Relationship of two human tRNA synthetases used in cell signaling. Trends Biochem Sci. 2004;29:250–256.
   PubMed Web of Science ®Google Scholar
• Sajish M, Zhou Q, Kishi S, et al. Trp-tRNA synthetase bridges DNA-PKcs to PARP-1 to link IFN-gamma and p53 signaling. Nat Chem Biol. 2012;8:547–554.
   PubMed Web of Science ®Google Scholar
• Spangle JM, Roberts TM, Zhao JJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta Rev Cancer. 2017;1868:123–131.
   PubMed Web of Science ®Google Scholar
• Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016;45:87–96.
   PubMed Web of Science ®Google Scholar
• Ham J, Lim W, Kim K, et al. Gentisyl alcohol inhibits proliferation and induces apoptosis via mitochondrial dysfunction and regulation of MAPK and PI3K/AKT pathways in epithelial ovarian cancer cells. Mar Drugs. 2019;17.
   Web of Science ®Google Scholar
• Yang H, Liu JX, Shang HX, et al. Qingjie Fuzheng granules inhibit colorectal cancer cell growth by the PI3K/AKT and ERK pathways. World J Gastrointest Oncol. 2019;11:377–392.
   PubMed Web of Science ®Google Scholar
• Li B, Yang J, Lu Z, et al. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway. J Buon. 2019;24:739–745.
   PubMed Web of Science ®Google Scholar
• Wang T, Seah S, Loh X, et al. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 2016;7:2532–2544.
   PubMedGoogle Scholar
• Xu Q, Simpson SE, Scialla TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003;102:972–980.
   PubMed Web of Science ®Google Scholar
• Tzima E, Reader JS, Irani-Tehrani M, et al. Biologically active fragment of a human tRNA synthetase inhibits fluid shear stress-activated responses of endothelial cells. Proc Natl Acad Sci U S A. 2003;100:14903–14907.
   PubMed Web of Science ®Google Scholar